比索洛尔逆转高血压左室心肌肥厚和纤维化的超声评价研究

Bisoprolol in Reversing Hypertensive Left Ventricular Hypertrophy and Fibrosis

目的 用超声心动图法评价以比索洛尔为代表的选择性 β肾上腺素受体阻滞剂对高血压左室肥厚和纤维化的逆转作用。方法 正常对照组 2 0例 ,高血压左室肥厚病人 2 3例为治疗组 ,口服比索洛尔 5mg/d共 2 4周 ,记录分析治疗组用药前后的三维超声心动图和声学密度定量指标 ,并与正常对照组比较。结果 治疗组在用药前后左室质量指数 (LVMI)均高于正常对照组 (P <0 .0 1) ,治疗组用药后LVMI显著减低 (P <0 .0 5 )。治疗组在用药前后的左室壁IBS %均高于正常对照组 (P <0 .0 5～ 0 .0 1) ,CVIBS低于正常对照组 (P <0 .0 5～ 0 .0 1) ,用药后较用药前左室壁IBS %降低 (P <0 .0 1) ,CVIBS增加 (P <0 .0 5 )。结论 比索洛尔可减轻高血压病人的左室肥厚和间质纤维化程度。

Objective To evaluate the effects of Bisoprolol, a selective β-adrenergic receptor blocker in reversing hypertensive left ventricular hypertrophy and fibrosis.Methods There were twenty three patients with hypertensive left ventricular hypertrophy treated with Bisoprolol (5mg/d for 24 weeks) in treatment group, while there were twenty patients treated without Bisoprolol as control group. Three dimensional echocardiography and acoustic densitometry were applied on all cases before and after treatment. Results Left ventricular mass index in treatment group were higher than that in control group (P<0.01) and it decreased after therapy (P<0.05). IBS% of left ventricular walls in treatment group was higher than that in control group (P<0.05-0.01)while CVIBS was lower (P<0.05-0.01). Comparing before and after treatment, IBS% of left ventricular walls in treatment group decreased (P<0.01) and CVIBS increased significantly (P<0.05). Conclusion Bisoprolol could improve hypertensive left ventricular hypertrophy and fibrosis.